Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to compare the effects of two different conditioning regimens on patients with acute lymphoblastic leukemia (ALL) undergoing haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT): Total Body Irradiation (TBI) and Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI). Both regimens are supported and recommended by literature; however, there is no definitive evidence favoring one over the other. We hypothesize that the TMLI regimen, compared to the TBI regimen, may more effectively eliminate leukemia cells in the bone marrow and lymphoid tissues, thereby reducing the risk of relapse, while also minimizing damage to normal tissues, thus reducing conditioning-related toxicity and transplant-related mortality. This study aims to provide evidence for the optimal conditioning regimen for haplo-HSCT in adult ALL patients, with the goal of improving patient quality of life and survival outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TMLI conditioning group | Experimental | Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI) plus Cyclophosphamide |
|
| TBI conditioning group | Active Comparator | Total Body Irradiation (TBI) plus Cyclophosphamide |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TBI | Radiation | The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Relapse-free survival (RFS) | RFS is defined as the time from transplantation to the first relapse or death, with RFS is defined as the time from transplantation to the first relapse or death, with the date of the last follow-up as the endpoint. | 2 years |
| acute Graft Versus Host Disease (aGVHD) | The incidence of aGVHD within 100 days post-transplant. | 100 days |
| Overall Survival (OS) | OS is defined as the time from transplantation to death, with the date of the last follow-up as the endpoint. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Transplantation Related Mortality (TRM) | The incidence of TRM in 2 years. | 100 days |
| Relapse Rate (RR) | The incidence ratio of leukemia relapse in 2 years. |
Not provided
Inclusion Criteria:
Informed Consent: Participants must voluntarily sign a written informed consent form.
Age and Gender: Participants should be male or female, aged 18-65 years, inclusive.
Diagnosis: Participants must be diagnosed with acute lymphoblastic leukemia (ALL) according to World Health Organization (WHO) criteria, and the diagnosis must apply to adults aged 18-65 years.
Remission Status: The participant's leukemia must be in hematologic remission (complete remission, CR) prior to transplantation.
Donor Availability: There must be a suitable haploidentical donor available, and the participant must consent to undergo haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
Karnofsky Performance Status: The participant must have a Karnofsky score of 70 or higher, indicating that they are capable of caring for themselves and carrying out normal activities. Additionally, they must not have significant organ dysfunction, defined by the following:
Reproductive Health:
Exclusion Criteria:
To be eligible for inclusion in the study, participants must not meet any of the following criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Zhilei Bian, PhD. | Contact | +86037166862278 | bianzhilei@zzu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Xiangbo Wan, PhD. | The First Affiliated Hospital of Zhengzhou University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Zhengzhou University | Recruiting | Zhengzhou | Henan | 450001 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| TMLI | Radiation | The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions. |
|
| Cyclophosphamide | Drug | The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3. |
|
|
| 2 years |
| Conditioning-related Adverse Events (CRAE) | Based on CTCAE v5.0. | 30 days |
| ID | Term |
|---|---|
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003520 | Cyclophosphamide |
| ID | Term |
|---|---|
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
Not provided
Not provided